ERICA TIDIANE: Open Payments
NPI 1205407095 · FOLSOM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,438 in 62 payments from 15 companies in 2025. Trend: 2023 $713 · 2024 $2,078 · 2025 $1,438
Food & beverage: $1,438
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $164 |
| Neuronetics, Inc. | 3 | $158 |
| ABBVIE INC. | 8 | $140 |
| Otsuka America Pharmaceutical, Inc. | 5 | $115 |
| Teva Pharmaceuticals USA, Inc. | 4 | $102 |
| Janssen Pharmaceuticals, Inc | 4 | $94 |
| Tris Pharma Inc | 4 | $88 |
| Bausch Health US, LLC | 4 | $88 |
| Lundbeck LLC | 3 | $72 |
Products named: REXULTI, INGREZZA, CAPLYTA, NEUROSTAR TMS THERAPY SYSTEM, VRAYLAR, AUSTEDO XR, SPRAVATO, Dyanavel XR.
Industry payments across CA — which companies pay providers there.
